Comparative Pharmacology
Head-to-head clinical analysis: FARXIGA versus INVOKANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARXIGA versus INVOKANA.
FARXIGA vs INVOKANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
10 mg orally once daily, with or without food.
100 mg orally once daily, before the first meal of the day; may increase to 300 mg once daily if tolerated and eGFR is adequate.
None Documented
None Documented
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Terminal elimination half-life is 10.6 hours (range 9.5–12.5 h) in healthy subjects; allows once-daily dosing. Half-life increases to 16 hours in moderate renal impairment and 22 hours in severe renal impairment.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Primarily excreted unchanged in urine (33%) and feces (52%) as parent drug and glucuronide metabolites; renal clearance accounts for 70% of total clearance, with 51% renally excreted as unchanged drug.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor